{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:35:54Z","timestamp":1760240154719,"version":"build-2065373602"},"reference-count":60,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T00:00:00Z","timestamp":1553472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Although Hodgkin lymphoma (HL) is highly curable with first-line therapy, relapses occur in approximately 10\u201320% of patients with early stage disease and 30\u201340% of patients with advanced stage disease. The standard approach for relapsed or refractory disease is salvage therapy, followed by consolidation with high dose therapy and autologous stem cell transplant (ASCT). Patients who achieve a complete response to salvage therapy prior to ASCT have better outcomes, thus recent studies have focused on incorporating newer agents in this setting. Major challenges in the management of relapsed patients remain how to choose and sequence the many salvage therapies that are currently available and how to best incorporate novel agents in the current treatment paradigms. In this article, we will summarize the most recent advances in the management of patients with recurrent HL and will mainly focus on the role of new agents approved and under investigation. Aside from brentuximab vedotin and checkpoint inhibitors, other novel agents and therapies are showing promising early results. However, at least with some of the newest targeted strategies, it is important to recognize that we are facing new challenges in terms of toxicities, which require very close monitoring and education of both the patient and treating physician.<\/jats:p>","DOI":"10.3390\/cancers11030421","type":"journal-article","created":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T05:03:12Z","timestamp":1553662992000},"page":"421","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Novel Therapies and Approaches to Relapsed\/Refractory HL Beyond Chemotherapy"],"prefix":"10.3390","volume":"11","author":[{"given":"Alain Antoine","family":"Mina","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Northwestern University Feinberg School of Medicine Chicago Illinois, Chicago, IL 60611, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chetan","family":"Vakkalagadda","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Northwestern University Feinberg School of Medicine Chicago Illinois, Chicago, IL 60611, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Pro","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Northwestern University Feinberg School of Medicine Chicago Illinois, Chicago, IL 60611, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,3,25]]},"reference":[{"key":"ref_1","unstructured":"Jaffe, E., Arber, D.A., Campo, E., Harris, N.L., and Quintanilla-Fend, L. (2016). Hematopathology. Hematopathology, Elsevier."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Johnson, P., Federico, M., Kirkwood, A., Foss\u00e5, A., Berkahn, L., Carella, A., d\u2019Amore, F., Enblad, G., Franceschetto, A., and Fulham, M. (2016). Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin\u2019s Lymphoma. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa1510093"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Josting, A., Rudolph, C., Mapara, M., Glossmann, J.P., Sienawski, M., Sieber, M., Kirchner, H.H., D\u00f6rken, B., Hossfeld, D.K., and Kisro, J. (2005). Cologne High-Dose Sequential Chemotherapy in Relapsed and Refractory Hodgkin Lymphoma: Results of a Large Multicenter Study of the German Hodgkin Lymphoma Study Group (GHSG). Ann. Oncol.","DOI":"10.1093\/annonc\/mdi003"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Moskowitz, C.H., Nimer, S.D., Zelenetz, A.D., Trippett, T., Hedrick, E.E., Filippa, D.A., Louie, D., Gonzales, M., Walits, J., and Coady-Lyons, N. (2001). A 2-Step Comprehensive High-Dose Chemoradiotherapy Second-Line Program for Relapsed and Refractory Hodgkin Disease: Analysis by Intent to Treat and Development of a Prognostic Model. Blood.","DOI":"10.1182\/blood.V97.3.616"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Bartlett, N.L., Niedzwiecki, D., Johnson, J.L., Friedberg, J.W., Johnson, K.B., van Besien, K., Zelenetz, A.D., Cheson, B.D., and Canellos, G.P. (2007). Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin (GVD), a Salvage Regimen in Relapsed Hodgkin\u2019s Lymphoma: CALGB 59804. Ann. Oncol.","DOI":"10.1093\/annonc\/mdm090"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Santoro, A., Magagnoli, M., Spina, M., Pinotti, G., Siracusano, L., Michieli, M., Nozza, A., Sarina, B., Morenghi, E., and Castagna, L. (2007). Ifosfamide, Gemcitabine, and Vinorelbine: A New Induction Regimen for Refractory and Relapsed Hodgkin\u2019s Lymphoma. Haematologica.","DOI":"10.3324\/haematol.10661"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Kuruvilla, J., Nagy, T., Pintilie, M., Tsang, R., Keating, A., and Crump, M. (2006). Similar Response Rates and Superior Early Progression-Free Survival with Gemcitabine, Dexamethasone, and Cisplatin Salvage Therapy Compared with Carmustine, Etoposide, Cytarabine, and Melphalan Salvage Therapy Prior to Autologous Stem Cell Transplantation for Recurrent or Refractory Hodgkin Lymphoma. Cancer.","DOI":"10.1002\/cncr.21587"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Moskowitz, C.H., Matasar, M.J., Zelenetz, A.D., Nimer, S.D., Gerecitano, J., Hamlin, P., Horwitz, S., Moskowitz, A.J., Noy, A., and Palomba, L. (2012). Normalization of Pre-ASCT, FDG-PET Imaging with Second-Line, Non-Cross-Resistant, Chemotherapy Programs Improves Event-Free Survival in Patients with Hodgkin Lymphoma. Blood.","DOI":"10.1182\/blood-2011-10-388058"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Kuruvilla, J., Keating, A., and Crump, M. (2011). How I Treat Relapsed and Refractory Hodgkin Lymphoma. Blood.","DOI":"10.1182\/blood-2010-09-288373"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Roemer, M.G.M., Advani, R.H., Ligon, A.H., Natkunam, Y., Redd, R.A., Homer, H., Connelly, C.F., Sun, H.H., Daadi, S.E., and Freeman, G.J. (2016). PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. J. Clin. Oncol.","DOI":"10.1200\/JCO.2016.66.4482"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V85.1.1.bloodjournal8511","article-title":"CD30 (Ki-1) Molecule: A New Cytokine Receptor of the Tumor Necrosis Factor Receptor Superfamily as a Tool for Diagnosis and Immunotherapy","volume":"85","author":"Falini","year":"1995","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Matsumoto, K., Terakawa, M., Miura, K., Fukuda, S., Nakajima, T., and Saito, H. (2004). Extremely Rapid and Intense Induction of Apoptosis in Human Eosinophils by Anti-CD30 Antibody Treatment in Vitro. J. Immunol.","DOI":"10.4049\/jimmunol.172.4.2186"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Bartlett, N.L., Younes, A., Carabasi, M.H., Forero, A., Rosenblatt, J.D., Leonard, J.P., Bernstein, S.H., Bociek, R.G., Lorenz, J.M., and Hart, B.W. (2008). A Phase 1 Multidose Study of SGN-30 Immunotherapy in Patients with Refractory or Recurrent CD30+ Hematologic Malignancies. Blood.","DOI":"10.1182\/blood-2007-07-099317"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Ansell, S.M., Horwitz, S.M., Engert, A., Khan, K.D., Lin, T., Strair, R., Keler, T., Graziano, R., Blanset, D., and Yellin, M. (2007). Phase I\/II Study of an Anti-CD30 Monoclonal Antibody (MDX-060) in Hodgkin\u2019s Lymphoma and Anaplastic Large-Cell Lymphoma. J. Clin. Oncol.","DOI":"10.1200\/JCO.2006.07.8972"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Alperovich, A., and Younes, A. (2016). Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma. Cancer J.","DOI":"10.1097\/PPO.0000000000000168"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Younes, A., Gopal, A.K., Smith, S.E., Ansell, S.M., Rosenblatt, J.D., Savage, K.J., Ramchandren, R., Bartlett, N.L., Cheson, B.D., and De Vos, S. (2012). Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin\u2019s Lymphoma. J. Clin. Oncol.","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Gandhi, M.D., Evens, A.M., Fenske, T.S., Hamlin, P., Coiffier, B., Engert, A., Moskowitz, A.J., Ghosh, N., Petrich, A.M., and Lomasney, J. (2014). Pancreatitis in Patients Treated with Brentuximab Vedotin: A Previously Unrecognized Serious Adverse Event. Blood.","DOI":"10.1182\/blood-2014-03-561878"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Moskowitz, C.H., Nademanee, A., Masszi, T., Agura, E., Holowiecki, J., Abidi, M.H., Chen, A.I., Stiff, P., Gianni, A.M., and Carella, A. (2015). Brentuximab Vedotin as Consolidation Therapy after Autologous Stem-Cell Transplantation in Patients with Hodgkin\u2019s Lymphoma at Risk of Relapse or Progression (AETHERA): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. Lancet.","DOI":"10.1016\/S0140-6736(15)60165-9"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Chen, R., Palmer, J.M., Martin, P., Tsai, N., Kim, Y., Chen, B.T., Popplewell, L., Siddiqi, T., Thomas, S.H., and Mott, M. (2015). Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed\/Refractory Hodgkin Lymphoma. Biol. Blood Marrow Transplant.","DOI":"10.1016\/j.bbmt.2015.07.018"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Moskowitz, A.J., Sch\u00f6der, H., Yahalom, J., McCall, S.J., Fox, S.Y., Gerecitano, J., Grewal, R., Hamlin, P.A., Horwitz, S., and Kobos, R. (2015). PET-Adapted Sequential Salvage Therapy with Brentuximab Vedotin Followed by Augmented Ifosamide, Carboplatin, and Etoposide for Patients with Relapsed and Refractory Hodgkin\u2019s Lymphoma: A Non-Randomised, Open-Label, Single-Centre, Phase 2 Study. Lancet Oncol.","DOI":"10.1016\/S1470-2045(15)70013-6"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Gandhi, V. (2002). Metabolism and Mechanisms of Action of Bendamustine: Rationales for Combination Therapies. Semin. Oncol.","DOI":"10.1016\/S0093-7754(02)90007-2"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Moskowitz, A.J., Hamlin, P.A., Perales, M.A., Gerecitano, J., Horwitz, S.M., Matasar, M.J., Noy, A., Palomba, M.L., Portlock, C.S., and Straus, D.J. (2013). Phase Ii Study of Bendamustine in Relapsed and Refractory Hodgkin Lymphoma. J. Clin. Oncol.","DOI":"10.1200\/JCO.2012.45.3308"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"LaCasce, A.S., Gregory Bociek, R., Sawas, A., Caimi, P., Agura, E., Matous, J., Ansell, S.M., Crosswell, H.E., Islas-Ohlmayer, M., and Behler, C. (2018). Brentuximab Vedotin plus Bendamustine: A Highly Active First Salvage Regimen for Relapsed or Refractory Hodgkin Lymphoma. Blood.","DOI":"10.1182\/blood-2017-11-815183"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Josting, A., Rudolph, C., Reiser, M., Mapara, M., Sieber, M., Kirchner, H.H., D\u00f6rken, B., Hossfeld, D.K., Diehl, V., and Engert, A. (2002). Time-Intensified Dexamethasone\/Cisplatin\/Cytarabine: An Effective Salvage Therapy with Low Toxicity in Patients with Relapsed and Refractory Hodgkin\u2019s Disease. Ann. Oncol.","DOI":"10.1093\/annonc\/mdf221"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Green, M.R., Monti, S., Rodig, S.J., Juszczynski, P., Currie, T., O\u2019Donnell, E., Chapuy, B., Takeyama, K., Neuberg, D., and Golub, T.R. (2010). Integrative Analysis Reveals Selective 9p24.1 Amplification, Increased PD-1 Ligand Expression, and Further Induction via JAK2 in Nodular Sclerosing Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma. Blood.","DOI":"10.1182\/blood-2010-05-282780"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Chen, B.J., Chapuy, B., Ouyang, J., Sun, H.H., Roemer, M.G.M., Xu, M.L., Yu, H., Fletcher, C.D.M., Freeman, G.J., and Shipp, M.A. (2013). PD-L1 Expression Is Characteristic of a Subset of Aggressive B-Cell Lymphomas and Virus-Associated Malignancies. Clin. Cancer Res.","DOI":"10.1158\/1078-0432.CCR-13-0855"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Ansell, S.M., Lesokhin, A.M., Borrello, I., Halwani, A., Scott, E.C., Gutierrez, M., Schuster, S.J., Millenson, M.M., Cattry, D., and Freeman, G.J. (2015). PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin\u2019s Lymphoma. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa1411087"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Younes, A., Santoro, A., Shipp, M., Zinzani, P.L., Timmerman, J.M., Ansell, S., Armand, P., Fanale, M., Ratanatharathorn, V., and Kuruvilla, J. (2016). Nivolumab for Classical Hodgkin\u2019s Lymphoma after Failure of Both Autologous Stem-Cell Transplantation and Brentuximab Vedotin: A Multicentre, Multicohort, Single-Arm Phase 2 Trial. Lancet Oncol.","DOI":"10.1016\/S1470-2045(16)30167-X"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Armand, P., Engert, A., Younes, A., Fanale, M., Santoro, A., Zinzani, P.L., Timmerman, J.M., Collins, G.P., Ramchandren, R., and Cohen, J.B. (2018). Nivolumab for Relapsed\/Refractory Classic Hodgkin Lymphoma after Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-up of the Multicohort Single-Arm Phase II Checkmate 205 Trial. J. Clin. Oncol.","DOI":"10.1200\/JCO.2017.76.0793"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Herrera, A.F., Moskowitz, A.J., Bartlett, N.L., Vose, J.M., Ramchandren, R., Feldman, T.A., LaCasce, A.S., Ansell, S.M., Moskowitz, C.H., and Fenton, K. (2018). Interim Results of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma. Blood.","DOI":"10.1182\/blood-2017-10-811224"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Armand, P., Shipp, M.A., Ribrag, V., Michot, J.M., Zinzani, P.L., Kuruvilla, J., Snyder, E.S., Ricart, A.D., Balakumaran, A., and Rose, S. (2016). Programmed Death-1 Blockade with Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure. J. Clin. Oncol.","DOI":"10.1200\/JCO.2016.67.3467"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Chen, R., Zinzani, P.L., Fanale, M.A., Armand, P., Johnson, N.A., Brice, P., Radford, J., Ribrag, V., Molin, D., and Vassilakopoulos, T.P. (2017). Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed\/Refractory Classic Hodgkin Lymphoma. J. Clin. Oncol.","DOI":"10.1200\/JCO.2016.72.1316"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/blood.V128.22.183.183","article-title":"Phase 1 Study of Nivolumab in Combination with Ipilimumab for Relapsed or Refractory Hematologic Malignancies (CheckMate 039)","volume":"128","author":"Ansell","year":"2016","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Dutton, A., Reynolds, G.M., Dawson, C.W., Young, L.S., and Murray, P.G. (2005). Constitutive Activation of Phosphatidyl-Inositide 3 Kinase Contributes to the Survival of Hodgkin\u2019s Lymphoma Cells through a Mechanism Involving Akt Kinase and MTOR. J. Pathol.","DOI":"10.1002\/path.1725"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Nagel, S., Scherr, M., Quentmeier, H., Kaufmann, M., Zaborski, M., Drexler, H.G., and MacLeod, R.A.F. (2005). HLXB9 Activates IL6 in Hodgkin Lymphoma Cell Lines and Is Regulated by PI3K Signalling Involving E2F3. Leukemia.","DOI":"10.1038\/sj.leu.2403716"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Jundt, F., Raetzel, N., M\u00fcller, C., Calkhoven, C.F., Kley, K., Mathas, S., Lietz, A., Leutz, A., and D\u00f6rken, B. (2005). A Rapamycin Derivative (Everolimus) Controls Proliferation through down-Regulation of Truncated CCAAT Enhancer Binding Protein \u03b2 and NF-\u0392B Activity in Hodgkin and Anaplastic Large Cell Lymphomas. Blood.","DOI":"10.1182\/blood-2004-11-4513"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Johnston, P.B., Inwards, D.J., Colgan, J.P., Laplant, B.R., Kabat, B.F., Habermann, T.M., Micallef, I.N., Porrata, L.F., Ansell, S.M., and Reeder, C.B. (2010). A Phase II Trial of the Oral MTOR Inhibitor Everolimus in Relapsed Hodgkin Lymphoma. Am. J. Hematol.","DOI":"10.1002\/ajh.21664"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Johnston, P.B., Pinter-Brown, L.C., Warsi, G., White, K., and Ramchandren, R. (2018). Phase 2 Study of Everolimus for Relapsed or Refractory Classical Hodgkin Lymphoma. Exp. Hematol. Oncol.","DOI":"10.1186\/s40164-018-0103-z"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Marks, P.A., and Xu, W.S. (2009). Histone Deacetylase Inhibitors: Potential in Cancer Therapy. J Cell Biochem.","DOI":"10.1002\/jcb.22185"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Lane, A.A., and Chabner, B.A. (2009). Histone Deacetylase Inhibitors in Cancer Therapy. J. Clin. Oncol.","DOI":"10.1200\/JCO.2009.22.1291"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Lemoine, M., Derenzini, E., Buglio, D., Medeiros, L.J., Davis, R.E., Zhang, J., Ji, Y., and Younes, A. (2012). The Pan-Deacetylase Inhibitor Panobinostat Induces Cell Death and Synergizes with Everolimus in Hodgkin Lymphoma Cell Lines. Blood.","DOI":"10.1182\/blood-2011-01-331421"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Younes, A., Sureda, A., Ben-Yehuda, D., Zinzani, P.L., Ong, T.C., Prince, H.M., Harrison, S.J., Kirschbaum, M., Johnston, P., and Gallagher, J. (2012). Panobinostat in Patients with Relapsed\/Refractory Hodgkin\u2019s Lymphoma after Autologous Stem-Cell Transplantation: Results of a Phase II Study. J. Clin. Oncol.","DOI":"10.1200\/JCO.2011.38.1350"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Oki, Y., Buglio, D., Fanale, M., Fayad, L., Copeland, A., Romaguera, J., Kwak, L.W., Pro, B., De Castro Faria, S., and Neelapu, S. (2013). Phase i Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma. Clin. Cancer Res.","DOI":"10.1158\/1078-0432.CCR-13-1906"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Hu, B., Younes, A., Westin, J.R., Turturro, F., Claret, L., Feng, L., Fowler, N., Neelapu, S., Romaguera, J., and Hagemeister, F.B. (2018). Phase-I and Randomized Phase-II Trial of Panobinostat in Combination with ICE (Ifosfamide, Carboplatin, Etoposide) in Relapsed or Refractory Classical Hodgkin Lymphoma. Leuk. Lymphoma.","DOI":"10.1080\/10428194.2017.1359741"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Younes, A., Oki, Y., Bociek, R.G., Kuruvilla, J., Fanale, M., Neelapu, S., Copeland, A., Buglio, D., Galal, A., and Besterman, J. (2011). Mocetinostat for Relapsed Classical Hodgkin\u2019s Lymphoma: An Open-Label, Single-Arm, Phase 2 Trial. Lancet Oncol.","DOI":"10.1016\/S1470-2045(11)70265-0"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Fehniger, T.A., Larson, S., Trinkaus, K., Siegel, M.J., Cashen, A.F., Blum, K.A., Fenske, T.S., Hurd, D.D., Goy, A., and Schneider, S.E. (2011). A Phase 2 Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma. Blood.","DOI":"10.1182\/blood-2011-07-362475"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Chanan-Khan, A.A., and Cheson, B.D. (2008). Lenalidomide for the Treatment of B-Cell Malignancies. J. Clin. Oncol.","DOI":"10.1200\/JCO.2007.14.5367"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Maly, J.J., Christian, B.A., Zhu, X., Wei, L., Sexton, J.L., Jaglowski, S.M., Devine, S.M., Fehniger, T.A., Wagner-Johnston, N.D., and Phelps, M.A. (2017). A Phase I\/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma. Clin. Lymphoma Myeloma Leuk.","DOI":"10.1016\/j.clml.2017.05.008"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Younes, A., Romaguera, J., Fanale, M., McLaughlin, P., Hagemeister, F., Copeland, A., Neelapu, S., Kwak, L., Shah, J., and De Castro Faria, S. (2012). Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes. J. Clin. Oncol.","DOI":"10.1200\/JCO.2012.42.5223"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Van Den Neste, E., Andr\u00e9, M., Gastinne, T., Stamatoullas, A., Haioun, C., Belhabri, A., Reman, O., Casasnovas, O., Ghesquieres, H., and Verhoef, G. (2018). A Phase II Study of the Oral JAK1\/JAK2 Inhibitor Ruxolitinib in Advanced Relapsed\/Refractory Hodgkin Lymphoma. Haematologica.","DOI":"10.3324\/haematol.2017.180554"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Phillips, T.J., Forero-Torres, A., Sher, T., Diefenbach, C.S., Johnston, P., Talpaz, M., Pulini, J., Zhou, L., Scherle, P., and Chen, X. (2018). Phase 1 Study of the PI3Kd Inhibitor INCB040093 6 JAK1 Inhibitor Itacitinib in Relapsed\/Refractory B-Cell Lymphoma. Blood.","DOI":"10.1182\/blood-2017-10-812701"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Kochenderfer, J.N., Dudley, M.E., Kassim, S.H., Somerville, R.P.T., Carpenter, R.O., Maryalice, S.S., Yang, J.C., Phan, G.Q., Hughes, M.S., and Sherry, R.M. (2015). Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated with Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor. J. Clin. Oncol.","DOI":"10.1200\/JCO.2014.56.2025"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Brentjens, R.J., Davila, M.L., Riviere, I., Park, J., Wang, X., Cowell, L.G., Bartido, S., Stefanski, J., Taylor, C., and Olszewska, M. (2013). CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia. Sci. Transl. Med.","DOI":"10.1126\/scitranslmed.3005930"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Turtle, C.J., Hanafi, L.A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., and Chen, X. (2016). Immunotherapy of Non-Hodgkin\u2019s Lymphoma with a Defined Ratio of CD8+and CD4+CD19-Specific Chimeric Antigen Receptor-Modified T Cells. Sci. Transl. Med.","DOI":"10.1126\/scitranslmed.aaf8621"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Ramos, C.A., Ballard, B., Zhang, H., Dakhova, O., Gee, A.P., Mei, Z., Bilgi, M., Wu, M.F., Liu, H., and Grilley, B. (2017). Clinical and Immunological Responses after CD30-Specific Chimeric Antigen Receptor-Redirected Lymphocytes. J. Clin. Invest.","DOI":"10.1172\/JCI94306"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Wang, C.M., Wu, Z.Q., Wang, Y., Guo, Y.L., Dai, H.R., Wang, X.H., Li, X., Zhang, Y.J., Zhang, W.Y., and Chen, M.X. (2017). Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase i Trial. Clin. Cancer Res.","DOI":"10.1158\/1078-0432.CCR-16-1365"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Grover, N.S., Park, S.I., Ivanova, A., Eldridge, P., McKay, K., Cheng, C.J., Laing, S., Covington, D., West, J., and Sharf, S.E. (2018). Clinical Responses to CAR.CD30-T Cells in Patients with CD30+ Lymphomas Relapsed after Multiple Treatments Including Brentuximab Vedotin. Blood.","DOI":"10.1182\/blood-2018-99-113534"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Bollard, C.M., Tripic, T., Cruz, C.R., Dotti, G., Gottschalk, S., Torrano, V., Dakhova, O., Carrum, G., Ramos, C.A., and Liu, H. (2018). Tumor-Specific t-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients with Relapsed Hodgkin Lymphoma. J. Clin. Oncol.","DOI":"10.1200\/JCO.2017.74.3179"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Younes, A., Bartlett, N.L., Leonard, J.P., Kennedy, D.A., Lynch, C.M., Sievers, E.L., and Forero-Torres, A. (2010). Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa1002965"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Gopal, A.K., Fanale, M.A., Moskowitz, C.H., Shustov, A.R., Mitra, S., Ye, W., Younes, A., and Moskowitz, A.J. (2017). Phase II Study of Idelalisib, a Selective Inhibitor of PI3K\u03b4, for Relapsed\/Refractory Classical Hodgkin Lymphoma. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.","DOI":"10.1093\/annonc\/mdx028"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/3\/421\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:40:25Z","timestamp":1760186425000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/3\/421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,25]]},"references-count":60,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3]]}},"alternative-id":["cancers11030421"],"URL":"https:\/\/doi.org\/10.3390\/cancers11030421","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2019,3,25]]}}}